国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

美國B(niǎo)G Medicine, Inc.
BG Medicine是一家致力于發(fā)現、開(kāi)發(fā)和商品化以生物標志物為基礎的新型分子診斷技術(shù)，并借此來(lái)改善患者治療結果和控制醫療費用的生命科學(xué)公司。該公司宣布，在D輪融資中獲得總額為4000萬(wàn)美元的資金。此輪融資包括新投資者Legg Mason Capital Management、GE Asset Management、SMALLCAP World Fund和現有投資者Flagship Ventures、Gilde Healthcare Partners、Humana、Stelios Papadopoulos。該筆資金將用于推動(dòng)公司現有的兩個(gè)診斷產(chǎn)品的研發(fā)和商業(yè)化，并將支持公司繼續進(jìn)行其他產(chǎn)品的研發(fā)。




BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. Our technology platform uniquely positions us to rapidly and cost-effectively discover new high-value biomarkers over a broad range of therapeutic categories that promise to be highly correlated to clinical outcomes. We have built a broad product pipeline that focuses on cardiovascular disease, cancer and CNS disorders through academic collaborations and initiatives with major pharmaceutical companies, the U.S Food and Drug Administration, or FDA and other healthcare organizations.

We discover biomarkers employing our proprietary, versatile, scalable technology platform that enables us to identify new biomarkers by integrating, and automating measurement, analysis, characterizations and interpretations of proteins and small non-protein biological molecules, or metabolites, collected from bodily fluids.

Through our biomarker discovery and product development programs we develop molecular diagnostic tests that are intended to provide information to physicians that will greatly improve patient treatment decisions. Our tests are designed to predict a patient’s response to drug therapy, determine the potential toxicity of therapeutic agents to patients, identify patients who have or are likely to develop a specific disease, predict a patient’s prognosis once a disease has been diagnosed and monitor a patient’s disease progression or drug response.